Abbott Laboratories (NYSE:ABT) Analysts Show Growing Optimism

Abbott Laboratories (NYSE:ABT) is a global healthcare company known for its diverse range of products, including medical devices, diagnostics, and nutritional products. On October 15, 2025, ABT reported earnings per share (EPS) of $1.30, matching the estimated EPS. The company generated revenue of approximately $11.37 billion, slightly below the estimated $11.39 billion.

The company's third-quarter sales increased by 6.9%, reaching $11.37 billion, as highlighted by Proactive Investors. This growth was driven by strong performance in Abbott's medical devices and diagnostics sectors, despite a normalization in COVID-19 testing-related revenue. Organic sales rose by 5.5%, or 7.5% when excluding COVID-19 testing-related revenue.

Abbott's operating margin was reported at 18.1% of sales, with an adjusted operating margin of 23%, marking a 40 basis point increase. The company's GAAP diluted EPS for the quarter stood at $0.94, while the adjusted diluted EPS was $1.30. This marks an increase from the $1.21 per share reported in the same quarter last year.

CEO Robert Ford emphasized the company's consistent, high-quality performance, attributing it to their differentiated product pipeline. Abbott has reaffirmed its full-year guidance, indicating confidence in its ongoing business strategy and market position. The company's price-to-earnings (P/E) ratio is approximately 16.07, reflecting the market's valuation of its earnings.

Abbott's financial metrics, such as a debt-to-equity ratio of approximately 0.27 and a current ratio of around 1.82, suggest a strong financial position. The company's enterprise value to sales ratio is around 5.36, providing insight into its valuation relative to its sales. Abbott's earnings yield is about 6.22%, offering a perspective on its earnings relative to its share price.

Abbott Laboratories (NYSE: ABT) is a global healthcare company known for its diverse range of products, including medical devices, diagnostics, and nutritional products. The company is set to release its third-quarter earnings on October 15, 2025. Analysts expect earnings per share (EPS) to be $1.30, reflecting a 7.4% increase from the previous year. Revenue is projected to reach $11.4 billion, up from $10.63 billion a year ago.

The anticipated EPS of $1.30 represents an 8.3% year-over-year growth, showcasing Abbott's strong performance. Despite this growth, the stock recently experienced a slight decline of 0.6%, closing at $132.57. This decline may be attributed to the market's high expectations for Abbott's performance, as highlighted by Citigroup analyst Joanne Wuensch, who maintained a Buy rating but adjusted the price target from $157 to $155.

Abbott's strategic focus on expanding its diabetes care solutions is a key driver for future growth. By transitioning from devices to comprehensive, data-driven care solutions, the company aims to strengthen its market position. This strategic move is expected to enhance Abbott's competitive edge and contribute to its long-term success in the healthcare industry.

Financially, Abbott maintains a strong position with a price-to-earnings (P/E) ratio of approximately 16.36 and a price-to-sales ratio of about 5.30. These metrics indicate the market's valuation of Abbott's earnings and revenue. Additionally, the company's debt-to-equity ratio of 0.27 suggests a relatively low level of debt, while a current ratio of 1.82 indicates strong liquidity to cover short-term liabilities.

The consensus earnings estimate for Abbott has been slightly adjusted downward by 0.1% over the past month. This adjustment reflects analysts' reassessment of their initial projections and could influence investor reactions. Empirical research shows a strong correlation between earnings estimate revisions and short-term stock price performance, making this a critical factor to watch as Abbott releases its earnings.

• Citigroup maintains a "Buy" rating for Abbott Laboratories (NYSE: ABT), with a current stock price of $124.17, indicating investor optimism.
• Abbott's diverse portfolio, healthy cash flow, and promising new product pipeline contribute to its positive outlook and growth potential.
• The company's stock has shown volatility but overall positive movement, with a trading volume of 10.76 million shares on the NYSE, reflecting active investor interest.

Abbott Laboratories (NYSE: ABT) is a global healthcare company known for its diverse portfolio, including medical devices, diagnostics, nutrition, and branded generic pharmaceuticals. The company competes with other healthcare giants like Johnson & Johnson and Medtronic. On July 18, 2025, Citigroup maintained its "Buy" rating for Abbott Labs, with the stock trading at around $124.50. The action associated with this rating is "hold," as highlighted by StreetInsider.

Abbott's strong buy recommendation for the second quarter of 2025 is supported by several factors. The company's robust management and diverse portfolio play a significant role in its positive outlook. Abbott's healthy cash flow and strategic capital return further enhance investor confidence. The promising pipeline of new products also contributes to the company's growth potential.

The current stock price of ABT is $124.17, showing an increase of approximately 3.04% or $3.66. This reflects investor optimism and confidence in the company's future prospects. Today, the stock has traded between a low of $122.27 and a high of $125.63, indicating some volatility but overall positive movement.

Over the past year, ABT has experienced a high of $141.23 and a low of $99.71. This range demonstrates the stock's potential for growth and the challenges it has faced. Despite these fluctuations, Abbott's market capitalization remains strong at approximately $216.04 billion, showcasing its stability and market presence.

The trading volume for ABT on the NYSE is 10.76 million shares, indicating active investor interest. This level of trading activity suggests that investors are closely monitoring Abbott's performance and are optimistic about its future. The combination of a strong buy recommendation, robust management, and a promising pipeline makes Abbott Laboratories an attractive investment opportunity.

Abbott Laboratories (NYSE:ABT) delivered better-than-expected first-quarter earnings and held firm on its full-year guidance, even as parts of its business felt the impact of a challenging macro environment.

The company reported adjusted earnings of $1.09 per share for the quarter, surpassing analyst expectations of $1.07 and improving from $0.98 a year earlier. Total revenue rose 4% year-over-year to $10.36 billion, just shy of the $10.4 billion forecast.

One of the quarter’s key growth drivers was Abbott’s diabetes care segment, which saw a 16% surge in revenue to $1.83 billion, fueled by continued demand for its FreeStyle Libre glucose monitoring system. That strength helped push total medical device sales to $4.9 billion.

However, softness in the diagnostics division weighed on results, with revenue from that unit falling 7.2% to $2.05 billion—below analysts’ estimates of $2.19 billion.

Despite mixed segment performance, Abbott reiterated its full-year 2025 guidance. The company still expects organic sales growth between 7.5% and 8.5%, and adjusted EPS in the range of $5.05 to $5.25. For the current quarter, adjusted earnings are projected between $1.23 and $1.27 per share.

Abbott Laboratories (NYSE:ABT) delivered better-than-expected first-quarter earnings and held firm on its full-year guidance, even as parts of its business felt the impact of a challenging macro environment.

The company reported adjusted earnings of $1.09 per share for the quarter, surpassing analyst expectations of $1.07 and improving from $0.98 a year earlier. Total revenue rose 4% year-over-year to $10.36 billion, just shy of the $10.4 billion forecast.

One of the quarter’s key growth drivers was Abbott’s diabetes care segment, which saw a 16% surge in revenue to $1.83 billion, fueled by continued demand for its FreeStyle Libre glucose monitoring system. That strength helped push total medical device sales to $4.9 billion.

However, softness in the diagnostics division weighed on results, with revenue from that unit falling 7.2% to $2.05 billion—below analysts’ estimates of $2.19 billion.

Despite mixed segment performance, Abbott reiterated its full-year 2025 guidance. The company still expects organic sales growth between 7.5% and 8.5%, and adjusted EPS in the range of $5.05 to $5.25. For the current quarter, adjusted earnings are projected between $1.23 and $1.27 per share.

• Abbott Laboratories (NYSE:ABT) reported an EPS of $1.09, surpassing estimates and showing improvement from the previous year.
• The company's revenue of $10.36 billion fell slightly short of estimates, but it reaffirmed its annual guidance with robust growth projections.
• Abbott's financial health is solid, with a P/E ratio of approximately 17.08 and a debt-to-equity ratio of approximately 0.32, indicating moderate debt levels and strong market valuation.

Abbott Laboratories, listed as NYSE:ABT, is a global healthcare company known for its diverse range of products, including medical devices, diagnostics, and nutritional products. The company competes with other major healthcare firms like Johnson & Johnson and Medtronic. Abbott's focus on innovation and quality has helped it maintain a strong position in the healthcare industry.

On April 16, 2025, Abbott reported earnings per share (EPS) of $1.09, surpassing the estimated $1.07. This performance marks an improvement from the previous year's EPS of $0.98, as highlighted by Zacks. Despite this earnings beat, the company's revenue of $10.36 billion fell slightly short of the estimated $10.41 billion.

Abbott's stock experienced a slight decline following the release of its first-quarter results, with a premarket trading price of $125.77. Despite the sales miss, the company reaffirmed its annual guidance, projecting adjusted earnings between $5.05 and $5.25 per share and organic sales growth of 7.5% to 8.5%. Analysts had forecasted earnings of $5.15 per share and total sales of $44.41 billion for the year.

The company's strong performance in the first quarter was driven by robust demand for its diabetes care products and other medical devices. This focus on the medical device segment has been a key growth area for Abbott. The company's price-to-earnings (P/E) ratio of approximately 17.08 indicates the market's valuation of its earnings, while its price-to-sales ratio of about 5.46 reflects the market's valuation of its revenue.

Abbott's financial health is further supported by its debt-to-equity ratio of approximately 0.32, suggesting a moderate level of debt relative to equity. The company's current ratio of about 1.67 indicates its ability to cover short-term liabilities with short-term assets. Additionally, Abbott's enterprise value to sales ratio is around 5.64, and its enterprise value to operating cash flow ratio is approximately 27.65, providing insights into its valuation relative to sales and cash flow.